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ABSTRACT
Morbidity and mortality of immunocompromised patients are increased by 
primary infection with or reactivation of Epstein-Barr virus (EBV), possibly triggering 
EBV+ post-transplant lymphoproliferative disease (PTLD). Adoptive transfer of 
EBV-specific cytotoxic T cells (EBV-CTLs) promises a non-toxic immunotherapy to 
effectively prevent or treat these complications. 
To improve immunotherapy and immunomonitoring this study aimed at identifying 
and evaluating naturally processed and presented HLA-A*03:01-restricted EBV-CTL 
epitopes as immunodominant targets. More than 15000 peptides were sequenced 
from EBV-immortalized B cells transduced with soluble HLA-A*03:01, sorted using 
different epitope prediction tools and eleven candidates were preselected. T2 and 
Flex-T peptide-binding and dissociation assays confirmed the stability of peptide-MHC 
complexes. Their immunogenicity and clinical relevance were evaluated by assessing 
the frequencies and functionality of EBV-CTLs in healthy donors (n > 10) and EBV+ 
PTLD-patients (n = 5) by multimer staining, Eli- and FluoroSpot assays. All eleven 
peptides elicited EBV-CTL responses in the donors. Their clinical applicability was 
determined by small-scale T-cell enrichment using Cytokine Secretion Assay and 
immunophenotyping. Mixtures of these peptides when added to the EBV Consensus 
pool revealed enhanced stimulation and enrichment efficacy. These EBV-specific 
epitopes broadening the repertoire of known targets will improve manufacturing 
of clinically applicable EBV-CTLs and monitoring of EBV-specific T-cell responses in 
patients.
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 4), pp: 4737-4757
INTRODUCTION
After hematopoietic stem cell (HSCT) and solid 
organ transplantation (SOT), patients are rendered highly 
susceptible to viral infections and reactivations due 
to transplant-related immunosuppressive therapy and 
delayed immune reconstitution. Therefore, infectious 
complications caused by endogenous herpes viruses like 
human cytomegalovirus (HCMV) and Epstein-Barr virus 
(EBV) or by lytic pathogens like human adenoviruses 
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(hAdV) are common and lead to increasing morbidity and 
mortality in immunocompromised patients [1].
Worldwide, more than 90% of adults have been 
infected with EBV [2], ensuring latent persistence via 
immune evasion. In healthy humans, viral replication is 
controlled by effective cytotoxic T lymphocytes (CTLs) 
against viral gene products expressed during the latent 
or lytic reactivation cycles of EBV and against cellular 
antigens [3]. In immunocompromised patients, however, 
viral replication cannot be controlled due to insufficient 
EBV-specific immunity. Consequently, reactivations and/
or outgrowth of latently EBV-infected B cells may occur 
leading to the development of high-grade lymphomas. 
Post-transplant lymphoproliferative disease (PTLD) 
represents the most common EBV-associated malignancy 
after transplantation. Up to 33% of primary infections post 
transplantation develop into true PTLD [4]. Reactivation of 
EBV in HSCT recipients ranges from 10 to 50%, while the 
incidences in SOT recipients vary from 1 to 20% depending 
on risk factors like EBV-serostatus, age at transplantation, 
immunosuppressive regimen post-transplant and organ graft 
[3, 5, 6]. The highest incidences following SOT (≤20%) have 
been detected in recipients of lung, small bowel or multiple 
organ grafts [3, 7, 8]. In general, EBV-seronegative patients 
with EBV-seropositive donors [7, 9] and EBV-seronegative 
transplant recipients suffering from primary EBV-infection 
in a post-transplant immunosuppressed setting [10, 11] 
carry the highest risk for PTLD development. Since 90% of 
pediatric and up to 70% of adult PTLDs [3, 12] are EBV-
associated, the two main immunotherapeutic approaches 
currently aim at eliminating the EBV-infected target cells 
and at restoring the patients’ long-term EBV-specific 
immunity [3, 5, 13–18]. Despite success in several patients, 
treatment with the chimeric monoclonal anti-CD20 antibody, 
rituximab, as first line therapy, is related to an increased risk 
of further infections in B-cell-depleted patients because of 
hypogammaglobulinemia. In addition, it is likely to remain 
ineffective due to several host- and tumor-related mechanisms 
[5, 19–22] and frequently leads to PTLD recurrences [5, 23]. 
Adoptive T-cell immunotherapy with donor derived 
EBV-specific T cells focuses on administering EBV-
specific T cells, which are specific to immunodominant 
latency-associated antigens expressed in PTLD, such 
as Epstein-Barr nuclear antigen 1 (EBNA1). In several 
clinical trials the adoptive transfer of functional EBV-
specific T cells from completely or partially HLA-
matched, EBV-seropositive donors has proven an 
effective, non-toxic immunotherapeutic approach to 
prevent and treat EBV-associated complications without 
increasing the risk of graft versus host disease (GvHD) 
[5, 13, 15–17, 22, 24]. 
The magnitude of T-cell responses to known 
immunodominant EBV-derived antigens (peptides, 
proteins and overlapping peptide pools), covering a wide 
range of HLA-restriction elements, considerably varies 
among EBV-seropositive healthy T-cell donors, thus 
indicating a high antigenic diversity [25–27]. Preliminary 
studies showed that 27% of EBV-seropositive healthy 
donors did not manifest immune responses to well-
established EBV target antigens (e.g. immediate-early 
protein BZLF1 (BZLF1), latent membrane protein 2A 
(LMP2A) and EBNA1) [27]. Evaluated EBV-specific 
T-cell epitopes are thus less immunodominant than those 
of the phosphoprotein 65 (pp65) of HCMV and therefore 
not able to elicit an immune response in every single EBV-
seropositive donor [25, 27]. Consequently, more than 
one EBV antigen is required for accurate monitoring of 
cellular immunity in patients, screening of potential T-cell 
donors and generation of effective EBV-specific T cells 
in sufficient numbers. This emphasizes the necessity of 
enlarging the repertoire of EBV-specific T-cell epitopes to 
both refine immunomonitoring and enhance multi-epitope-
based EBV-specific immunotherapeutic strategies.
This study aims at the identification of novel HLA-
A*03:01-restricted EBV-specific CD8+ T-cell epitopes 
presented in vivo by EBV-infected target cells. To ensure 
in vivo and clinical relevance, EBV-derived peptides were 
deliberately isolated from EBV-immortalized, HLA-
A*03:01-lentivirally transduced B-lymphoblastoid cell 
lines (B-LCLs), acting as surrogate cells for PTLD [5]. 
Immunogenicity, cytotoxicity and clinical eligibility of 
eleven CTL candidate epitopes were evaluated. The newly 
identified, immunodominant EBV-specific CTL epitopes 
will improve (1) the accurate monitoring of EBV-specific 
T-cell immune responses in patients before and after 
transplantation, (2) the identification of suitable T-cell 
donors as well as (3) the manufacturing of clinical-grade 
antiviral T cells in a sufficient cell number for the adoptive 
transfer to ameliorate the clinical outcome of patients 
suffering from EBV-related complications.
RESULTS
Verification of in vivo isolated HLA-A*03:01-
restricted EBV-derived peptides 
A combination of different epitope prediction tools 
was applied to scan the unfiltered sequences of HLA-
A*03:01-restricted EBV-derived peptides isolated in vivo. 
The secretion of soluble HLA-A*03:01 (sHLA-A*03:01) 
in the transduced EBV+B-LCLs’ supernatants reached levels 
up to 6.85 μg/ml (mean: 4.15 ± 1.93 μg/ml). A total of about 
15,000 unfiltered EBV-specific peptide-sequences were 
isolated in vivo (Supplementary Figure 1). Among these, 
only 4.49% of the sequences (n = 673) remained after the 
first sorting exclusively based on the peptide-ion-score. As 
this particular score is not completely congruous with the 
quality of the sequence’s MS/MS-spectrum, this relatively 
low cut-off value was chosen [38]. Resulting from the cut-
off value of 15%RANK (NetMHC) 32.4% (n = 218) of the 
673 ranked sequences remained candidates. Subsequent to 
the scanning of the candidates by NetMHC, NetCTL and 
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NetMHCstab, the 20 highest scoring sequences of each 
EBV+B-LCL or those classified as strong [SB] or weak 
binders [WB] (n = 63) were comparatively analyzed by 
ExPASy-ProtParam-tool and SYFPEITHI. 17.5% of the 
remaining sequences (n = 11) answered the additional 
criterion of not presenting any homologies to the human 
genome (Table 1). Most of them derive from proteins 
associated with either latency and/or reactivation or with 
potential to promote malignant transformation. In this 
context A*03_BTRF1FLGK represents the only exception 
as it derives from EBV protein BTRF1 that has not been 
characterized yet. Considering the HLA-A*03:01 peptide 
supermotif with focus on the primary anchor positions P2 
and P9 [45, 46], all eleven EBV-peptide sequences carry 
one of the highly preferred amino acids at P2 (A, I, L, T, 
V, M, S). Eight of them contain the typically preferred 
residues at P9 (K, R). Taking all the mentioned criteria 
into account, these eleven EBV-specific peptide-sequences 
continued to be potentially relevant as novel T-cell epitopes 
and therefore appropriate for further investigation (Table 1). 
Four of them were predicted as strong and six of them as 
weak binders (NetMHC). These predicted binding affinities 
were confirmed by SYFPEITHI-scores ranging from 20 
to 31, except for A*03_BILF2VTLA. Ten EBV-derived 
sequences were predicted to be ‘potential CTL epitopes’ 
by NetCTL with combined scores ranging from 0.748 to 
1.676. Stability of the pMHC complexes was considered to 
be either highly or weakly stable (NetMHCstab) in ten of 
the sequences, confirmed by the instability indices obtained 
from the ExPASy-ProtParam-tool, classifying all eleven 
sequences to be stable. In summary, eleven in vivo isolated 
HLA-A*03:01-restricted EBV-derived peptides (Table 1) 
were found to be potentially relevant according to their 
respective epitope prediction scores and were therefore 
further on investigated.
Immunogenic potential and functionality of the 
eleven EBV-peptide-specific T-cell epitopes
Proof of immunodominance by IFN-γ secretion 
Peptides from the eleven, highest scoring 
sequences (Table 1) were then synthesized and screened 
in interferon-gamma (IFN-γ) EliSpot assay to evaluate 
their immunogenicity in short- (1 day) and long-term (7 
days) in vitro stimulation assays (Figure 1). Unspecific 
T-cell responses to the evaluated peptides were not 
observed in peripheral blood mononuclear cells (PBMCs) 
from healthy donor controls (HLA-A*03:01+EBV– or 
HLA-A*03:01–EBV+, data not shown). After short-term 
overnight in vitro stimulation only low numbers of spots 
per well (spw) could be detected ranging from 0.36 ± 0.59 
(A*03_BILF2VTLA, n = 21) to 3.73 ± 6.27 spw (A*03_
gBKIVT, n = 10, Figure 1A). In comparison to the known 
immunodominant reference peptide A*03_EBNA3ARLRA, 
the latter revealed a higher stimulating efficacy following 
short-term in vitro stimulation (4.93 ± 4.85 spw, n = 18, 
Figure 1A) than the newly identified peptides.
All eleven newly identified EBV-specific peptides 
were capable of inducing an EBV-specific T-cell response 
in ≥20% of the donors after 7 days of in vitro stimulation 
and were therefore classified as immunodominant (Table 1, 
Figure 1B). The long-term in vitro stimulation with 
A*03_EBNA3ARLRA led to positive responses in 50% 
of the donors (n = 9/18) with specific T-cell responses 
ranging from 0.0 to 191.7 spw (29.1 ± 54.5 spw, Figure 
1B), representing an average increase of spw by 5.9-
fold in comparison to day 1 (Figure 1C). IFN-γ EliSpot 
assays following long-term stimulation showed increased 
numbers of spw for the new epitopes, ranging from 2.67 
± 3.82 (A*03_BPLF1KLLR) to 46.0 ± 71.0 spw (A*03_
BTRF1FLGK, Figure 1B) with an average increase of spw 
of 28-fold (Figure 1C). The peptides A*03_BILF2VTLA, 
A*03_BcRF1FLLA, A*03_BALF3QVAT and A*03_BILF2LIIP 
elicited a specific T-cell response in more than 50% of 
the assessed donors and were consequently classified as 
highly immunodominant with specific response rates of up 
to 68.4% (A*03_BcRF1FLLA, n = 19, Table 1). The highest 
number of spw of these epitopes was determined following 
the EBV-peptide-specific stimulation with A*03_
BcRF1FLLA (35.1 ± 47.7 spw, Figure 1B). As compared 
to the determined fold increase of the reference peptide 
A*03_EBNA3ARLRA, the long-term stimulation with one 
of the four highly immunodominant peptides resulted 
in higher rises of spw, reflected by average increases 
of 78.4- (A*03_BILF2VTLA), 71.4- (A*03_BcRF1FLLA), 
30.4- (A*03_BALF3QVAT) and 44.8-fold (A*03_BILF2LIIP, 
Figure 1C). In short, the high immunodominance of the 
peptides A*03_BILF2VTLA, A*03_BcRF1FLLA, A*03_
BALF3QVAT and A*03_BILF2LIIP was confirmed by strong 
IFN-γ secretion levels after long-term stimulation. 
Increase of IFN-γ response in comparison to the mere 
EBV_Consensus pool
Addition of the four highly immunodominant 
peptides to the well-established peptide pool EBV_
Consensus (Table 1, EBV_Consensus+4PMIX) yielded 
increased numbers of detectable EBV-specific T cells 
following both short- and long-term in vitro stimulation in 
comparison to the stimulation with the EBV_Consensus 
alone (Figure 1D). Short-term in vitro stimulation with 
EBV_Consensus+4PMIX led to a 11.5 higher mean value of 
spw than stimulation with the mere EBV_Consensus and to 
5.94% more spw per 1000 CD3+ T cells (data not shown). 
Proof of immunodominance by detection of 
cytotoxicity and cytokine secretion
Apart from evaluating the immunogenicity by 
detection of IFN-γ secretion, the cytotoxic functionality 
of the EBV-specific peptide-induced T cells was assessed. 
After 7 days of in vitro stimulation with one of the eleven 
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EBV-derived candidate-peptides, secretion levels of IFN-γ 
(Figure 2A) and granzyme B (Figure 2B) in supernatants 
were therefore determined. Secretion levels were 
comparable or even higher in comparison to the reference 
peptide A*03_EBNA3ARLRA (IFN-γ: 1671 ± 2802 pg/ml; 
granzyme B: 3209 ± 2510 pg/ml, data not shown). The 
IFN-γ secretion levels in response to the newly identified 
immunodominant peptides were visualized as percentages 
in correlation to those of the reference peptide A*03_
EBNA3ARLRA, which were set to a comparative value of 
100%. They ranged from 113.2 ± 41.2% (A*03_gBKIVT) 
to 765.2 ± 516.5% (A*03_BcRF1FLLA, Figure 2A). The 
granzyme B secretion levels varied between 52.9 ± 12.2% 
(A*03_gBKIVT) and 813.4 ± 489.6% (A*03_BcRF1FLLA, 
Figure 2B). Thus, the peptide A*03_BcRF1FLLA 
consistently induced the highest secretion of IFN-γ and 
of granzyme B, which were significantly higher than 
those induced by the reference peptide (***p < 0.001). The 
stimulating efficacy of the mixture EBV_Consensus+4PMIX 
compared to the EBV_Consensus revealed a 13.8-
fold higher IFN-γ secretion (EBV_Consensus: 844.0% 
versus EBV_Consensus+4PMIX: 11642.0%, Figure 2A). 
Regarding granzyme B, the stimulation with EBV_
Consensus+4PMIX led to a 2.73-fold higher concentration 
than the stimulation with the mere peptide pool (EBV_
Consensus: 526.2% versus EBV_Consensus+4PMIX: 
1439.0%, Figure 2B).
IFN-γ/granzyme B FluoroSpot assay to confirm the 
high immunodominance of four of the EBV-derived 
peptides as single stimulants and in combination 
The immunogenic and cytotoxic functionality of the 
four newly identified highly immunodominant peptides 
was further affirmed by IFN-γ/granzyme B FluoroSpot 
assay (Supplementary Figure 2). The highest values for 
IFN-γ producing cells were detected with A*03_BcRF1FLLA 
(1.70 ± 1.48 spw) and A*03_BALF3QVAT (1.69 ± 1.79 spw, 
Supplementary Figure 2). The stimulation with the reference 
peptide A*03_EBNA3ARLRA however led on average to a 
1.55-fold higher amount of IFN-γ producing cells (2.60 ± 
3.27 spw). With respect to the cytotoxic T-cell activity, A*03_
EBNA3ARLRA induced on average a 0.59-fold lower number 
of granzyme B producing cells (0.70 ± 1.10 spw) than 
A*03_BcRF1FLLA (0.80 ± 1.79 spw) and A*03_BALF3QVAT 
(1.57 ± 3.32 spw, Supplementary Figure 2). Similar to the 
respective numbers of IFN-γ producing cells, the stimulation 
Table 1:  In vivo  isolated, highly scored EBV-specific candidate-epitopes–in silico predicted results and IFN-γ EliSpot-
based screening for immunogenicity
Sequence Origin Abbreviation
Epstein-Barr-Virus-
Protein
Peptide-
Ion-Score
NetMHC 4.0 NetCTL 1.2 
NetMHCstab 
1.0 
ExPASy-
ProtParam tool
SYF-
PEITHI
Responders
[aa] [B-LCL] [UniProtKB-Database] [pep_score] [%Rank] [BL] [score] [E] [score] [BL]
[Instab.- 
Index]
[class.] [score]
[IFN-γ EliSpot 
(day 7)]
RLRAEAQVK A*03_EBNA3ARLRA
Ebstein-Barr-Nuclear-
Antigen-3A–EBNA-3A 0.40 SB 1.4208 E 0.633
SB  
HS 18.71 stable 36 9/18
KLLRYASAK in vivo  [024] A*03_BPLF1KLLR
Large tegument protein 
deneddylase–BPLF1 13.57 0.01 SB 1.6755 E 0.785
SB  
HS 38.79 stable 35 5/14
TVARHLLGAK in vivo  [623] A*03_BALF5TVAR
DNA polymerase catalytic 
protein - BALF5 13.30 0.15 SB 0.7951 E 0.586
SB  
WS 19.77 stable 26 7/14
ATGMVPAVKK in vivo  [623] A*03_BBRF1ATGM
Portal protein UL6 
homolog–BBRF1 28.73 0.20 SB 0.9726 E 0.431 WB 36.15 stable 20 2/10
KLVCSEPLVK
in vivo  
[024, 
623]
A*03_BcRF1KLVC TBP-like protein - BcRF1 30.29 0.40 SB 0.9152 E 0.597
WB  
WS 36.15 stable 31 5/14
VTLAHAGYY
in vivo 
[1335]
A*03_BILF2VTLA
 (1),(2) Glycoprotein–BILF2 49.38 0.70 WB 1.2361 E 0.419 WB –5.70 stable 14 13/21
FLLAMTSLR
in vivo  
[623]
A*03_BcRF1
FLLA 
(1),(2) TBP-like protein–BcRF1 12.90 0.70 WB 1.4480 E 0.347 WB 27.09 stable 21 13/19
FLGKYIKVKK in vivo  [024] A*03_BTRF1FLGK
„uncharacterized protein“–
BTRF1 16.21 1.00 WB 1.1954 E 0.357 WB –19.35 stable 24 5/10
QVATEGLAK
in vivo 
[024]
A*03_BALF3
QVAT 
(1),(2)
Tripartite terminase 
subunit UL28 homolog–
BALF3
18.17 1.20 WB 0.9267 E 0.414 WB  WS 21.91 stable 30 12/19
TLVDVRAIK in vivo  [623] A*03_BaRF1TLVD
Ribonucleoside-
diphosphate reductase small 
chain–BaRF1
16.60 1.20 WB 1.0387 E 0.415 WB –17.24 stable 26 5/14
KIVTNILIY in vivo  [024] A*03_gBKIVT
envelope glycoprotein 
B–gB 10.09 1.30 WB 1.2615 E 0.346 WB 34.11 stable 20 2/10
LIIPNVTLAH
in vivo 
[1335]
A*03_BILF2
LIIP 
(2) Glycoprotein–BILF2 49.38 4.00 0.7476 0.239 –10.86 stable 22 11/20
[aa] = amino acid, [B-LCL] = B-lymphoblastoid cell line, (1) = component of EBV_Consensus+3PMIX, 
(2) = component of EBV_Consensus+4PMIX,  [Ref.] = References, [pep_score] = peptide score (sequences’ 
probability of an existent match to a database entry), [BL] = Binding Level, [SB] =  strong binder, [WB] = weak binder, [HS] = highly stable binder, [WS] = weakly stable binder, [score] = combined prediction 
score, [E] = identified as potential CTL epitope, [Instab.-Index] = Instability Index, [class.] = classification.
Overview of the eleven investigated HLA-A*03:01-restricted candidate-epitopes and the known A*03_EBNA3ARLRA as reference epitope regarding their peptide sequences, origin, protein source, analyzed prediction 
scores (NetMHC 4.0, NetCTL 1.2, NetMHCstab 1.0, ExPASy-ProtParam tool, SYFPEITHI) and in vitro T-cell responses (IFN-γ EliSpot assay). All isolated sequences with a peptide-ion-score >10 [pep_score] 
that reached the highest scores in the subsequent predictions regarding their peptide-binding affinity and peptide-MHC complex stability as well as with a clinically relevant role in EBV-latency, -reactivation and/
or potentially malignant transformation are included. Candidate-epitopes were classified as immunodominant (immunoresponse in ≥20% of donors) and highly immunodominant (immunoresponse in >50% of the 
donors, as typed in bold) assessed by in vitro IFN-γ EliSpot assay.
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with A*03_BILF2VTLA and A*03_BILF2LIIP resulted in low 
numbers of granzyme B producing cells. 
The stimulation with one of the three applied mixtures 
EBV_Consensus+3PMIX, EBV_Consensus+4PMIX and EBV_
Consensus+11PMIX triggered the secretion of both IFN-γ 
and granzyme B (Figure 3). The results were in line with 
the higher stimulating efficacy obtained via IFN-γ EliSpot 
assays and demonstrated a step-by-step enhancement of 
28.1% (182.6 ± 122.4 spw, EBV_Consensus+3PMIX), 39.3% 
(198.6 ± 127.4 spw, EBV_Consensus+4PMIX) and 67.0% 
(238.2 ± 136.9 spw, EBV_Consensus+11PMIX), as compared 
to the IFN-γ producing cells induced by EBV_Consensus 
(142.6 ± 94.5 spw, Figure 3). Correspondingly, this stepwise 
enhancement was determined in regard to the cytotoxic 
T-cell activity mirrored by the quantification of granzyme B 
producing cells, unveiling an enhancement of 53.6% (78.6 ± 
51.8 spw, EBV_Consensus+3PMIX), 64.8% (84.4 ± 57.8 spw, 
EBV_Consensus+4PMIX) and 136.7% (121.2 ± 99.2 spw, 
EBV_Consensus+11PMIX) in comparison to the stimulation 
with just the EBV_Consensus (51.2 ± 46.6 spw, Figure 3). 
The obtained results confirmed the immunodominance 
of the eleven EBV-specific T-cell epitopes, showed that 
the stimulation capacity of an established peptide pool 
can be improved and underlined the classification of the 
four peptides A*03_BILF2VTLA, A*03_BcRF1FLLA, A*03_
BALF3QVAT and A*03_BILF2LIIP as highly immunodominant.
Figure 1: (A–D) Screening for HLA-A*03:01-restricted EBV-peptide-specific T cells by IFN-γ EliSpot. EBV-specific T-cell responses 
elicited by EBV-derived candidate-peptides were determined by IFN-γ EliSpot assays using PBMCs from healthy HLA-A*03:01-positive 
and EBV-seropositive donors (n ≥ 10). The known immunodominant HLA-A*03:01-specific T-cell epitope A*03_EBNA3ARLRA and the 
available PepTivator EBV Consensus (EBV_Consensus) served as references. Results are indicated as the number of spots per well (spw) 
after the number of spw of the respective negative control has been subtracted from that one of the antigen well. Based on the cut-off value 
of >3 peptide-induced spw, donors were identified as positive responders. EBV-peptides initiating an immune response in >50% of the 
donors after seven days of in vitro stimulation were classified as highly immunodominant. IFN-γ EliSpot assays after (A) short-term (day 1) 
and (B) long-term (day 7) in vitro stimulation with one of the peptides. (C) The capacity of the EBV-peptides to generate EBV-specific 
T cells subsequent to long-term in vitro stimulation is separately demonstrated for each of the peptides by the resultant fold increases 
of spw. (D) The immunogenic potential of the respective peptides to reinforce available peptide pools (e.g. EBV_Consensus) was 
evaluated by means of comparing the resultant spw ensuing stimulation (‘day 1’ and ‘day 7’) with EBV_Consensus+4PMIX (Table 1) to 
the respective values of the mere EBV_Consensus. Numbers of spw, too high to be individually detected by the EliSpot reader (>508 spw 
based on the highest determined count of spw), are indicated by the broken line. Results are displayed as individual results and means ± 
standard deviation (SD). Asterisks indicate statistically significant differences between the EBV-specific peptides and A*03_EBNA3ARLRA 
(**p < 0.01, ***p < 0.001).
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Confirmation of the EBV-derived peptides’ in 
vitro binding and dissociation
To confirm the in vitro peptide binding and the 
stability of the peptide-HLA-A*03:01 (pHLA-A*03:01)-
complexes, Flex-T and T2 peptide binding and dissociation 
assays were performed. The peptide-MHC (pMHC)-
binding capacity of all eleven newly identified peptides to 
HLA-A*03:01 monomers was assessed using the Flex-T 
assay (Figure 4A). The three peptides, A*03_BPLF1KLLR 
(2.29 OD414), A*03_BALF5TVAR (2.32 OD414) and A*03_
BcRF1KLVC (2.37 OD414), all of them predicted to be 
either strong or weak binders (Table 1), revealed strong 
binding to HLA-A*03:01 as shown by the highest optical 
densities (OD). The other candidates displayed ODs in 
the range of the negative control peptides. The lowest 
Figure 2: (A–B) Quantification of IFN-γ and granzyme B secretion by ELISA. Secretion of IFN-γ and granzyme B in response to the 
stimulation with one of the respective peptides was analyzed by quantitative ELISA after in vitro antigen-specific stimulation over seven 
days (n = 5). The referential antigens (A*03_EBNA3ARLRA, EBV_Consensus) were additionally employed as antigenic stimuli. Results 
of (A) IFN-γ and (B) granzyme B secretion (pg/ml) are shown for each of the peptides and EBV_Consensus+4PMIX as the percentage 
concentration in reference to the peptide A*03_EBNA3ARLRA, which is set to a comparative value of 100%. They are displayed as means 
± SD. Asterisks indicate statistically significant differences between the EBV-specific peptides and A*03_EBNA3ARLRA (
***p < 0.001). 
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absorbance was detected for the A*03_gBKIVT-specific 
monomer (0.28 OD414), predicted to be a weak binder. The 
ELISAs for three of the four peptides classified as highly 
immunodominant also resulted in low absorbance values 
(0.32–0.47 OD414). 
Peptide-binding and stability of the pHLA-
A*03:01-complexes of the four highly immunodominant 
candidate-peptides were furthermore investigated by 
T2 peptide binding and dissociation assay (Figure 4B). 
Peptide binding as indicated by the first time point (t1) was 
higher for all four peptides than for the reference peptide 
A*03_EBNA3ARLRA (0.17 ± 0.24 FI) with fluorescence 
indexes (FIs) ranging from 0.25 ± 0.41 (A*03_BcRF1FLLA) 
to 0.72 ± 0.51 (A*03_BILF2LIIP, n = 3, Figure 4B). The 
highest binding capacity was detected for A*03_BILF2LIIP 
revealing a 4.22-fold higher FI than A*03_EBNA3ARLRA. 
Interestingly, the predictions of both the peptide-binding 
affinity (Table 1) and the half-life for A*03_BILF2LIIP were 
however the lowest of all these eleven newly identified 
EBV-derived peptides. After 60 minutes (t2) the FI values 
for the four pMHC complexes were on average 93.3% 
lower than those quantified at t1. A*03_BcRF1FLLA unveiled 
the fastest dissociation, since no FI value was detectable 
after 60 minutes (t2), which corresponded to the predicted 
short half-life of 0.55 hours (NetMHCstab, www.cbs.dtu.
dk/services/NetMHCstab-1.0/, data not shown). A step-
by-step dissociation was observed for A*03_BILF2VTLA 
and A*03_BILF2LIIP with FI values at t2 being 89.1% and 
95.8% lower, respectively, than at t1. The highest FI value 
at t2 was detected in response to A*03_BALF3QVAT (Figure 
4B), thus in line with the predicted half-life of 2.57 hours 
(NetMHCstab, www.cbs.dtu.dk/services/NetMHCstab-1.0, 
data not shown). Although the FI values of t1 for all four 
peptides decreased by on average 97.6% after 120 minutes 
(t3, Figure 4B), a certain number of peptide-specific pMHC 
complexes, as mirrored by the FI values, revealed to be 
stable and was thus detectable. 
Comparing the prediction scores to the results of both 
the Flex-T assay and the in vitro T2 dissociation assay, the 
reference peptide A*03_EBNA3ARLRA revealed the highest 
pMHC complex stability, followed by the candidate-peptide 
A*03_BALF3QVAT. The peptide-binding capacity of the four 
highly immunodominant peptides was confirmed by the 
HLA class I binding and dissociation assay.
Peptide-specific T cells detectable in peripheral 
blood of healthy donors without prior 
stimulation
The precursor frequencies of circulating CD8+ CTLs 
specific to the newly identified, highly immunodominant 
EBV-derived epitopes A*03_BILFVTLA, A*03_BcRF1FLLA 
Figure 3: Evaluation of the immunogenic and cytotoxic activity of the peptide-induced EBV-specific T cells. The cytotoxic 
activity of peptide-induced EBV-specific T cells was investigated by means of IFN-γ and granzyme B FluoroSpot assays. PBMCs 
from healthy HLA-A*03:01-positive, EBV-seropositive donors (n = 5) were stimulated with one of the three peptide-mixtures (EBV_
Consensus+3PMIX, EBV_Consensus+4PMIX, EBV_Consensus+11PMIX, Table 1). The mere EBV_Consensus served as referential antigen. 
Spots identified with the filter for FITC represented IFN-γ producing cells and spots identified by the filter for Cy3 detected granzyme 
B producing cells. Results are given as the number of spots per well (spw), representing the number of spots in the antigen well after 
subtracting those of the respective negative control well. They are displayed as means ± SD.
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and A*03_BALF3QVAT were determined by multimer staining 
in freshly isolated PBMCs of healthy donors (Figure 5, 
Supplementary Figure 4). In comparison to the reference 
peptide A*03_EBNA3ARLRA (0.54%, range: 0–2.31%), 
the detectable peptide-specific CTLs reached frequencies 
ranging from 0.44 ± 0.70 to 0.97 ± 1.08% (Figure 5). The 
frequencies of circulating CTLs specific to A*03_BALF3QVAT 
(0.44% range: 0–1.66%) were lower than those specific 
to A*03_BILF2VTLA (0.97%, range: 0.15–2.82%) and 
A*03_BcRF1FLLA (0.82%, range: 0.02–3.09%, Figure 5). 
T-cell responses against A*03_BILF2VTLA (n = 3/5), A*03_
BcRF1FLLA (n = 3/5) and A*03_EBNA3ARLRA (n = 2/5) 
as detected by multimer staining were consistent with the 
corresponding IFN-γ EliSpot results. Regarding the peptide 
A*03_BALF3QVAT, a lower number of positive donors 
(n = 2/5) was identified by multimer staining in comparison 
to IFN-γ EliSpot (Figure 1B). 
Efficient enrichment of EBV-specific CTLs 
induced by the newly identified highly 
immunodominant CTL epitopes 
Enriching the IFN-γ secreting T cells via stimulation 
with the single peptides 
IFN-γ cytokine secretion assay (CSA) was further 
on performed to evaluate the in vivo identified peptides as 
suitable target antigens for the generation of clinical-grade 
EBV-specific T cells (Figure 6). All four investigated 
candidate-peptides triggered on average 33.4% higher 
numbers of IFN-γ-producing CD3+ T cells in the origin 
fraction than the reference peptide A*03_EBNA3ARLRA 
(A*03_EBNA3ARLRA: 0.08 ± 0.01%, A*03_BILF2VTLA: 
0.10 ± 0.04%, A*03_BcRF1FLLA: 0.14 ± 0.07%, A*03_
BALF3QVAT: 0.09 ± 0.04%, A*03_BILF2LIIP: 0.10 ± 0.04%, 
Figure 6A). The highest frequencies of IFN-γ+CD8+ T cells 
were observed for A*03_BcRF1FLLA (0.17 ± 0.08%). The 
total number of IFN-γ+CD3+ T cells in the origin fraction 
is shown in Supplementary Figure 3A. 
The enrichment process led to frequencies of IFN-
γ-secreting CD3+ T cells ranging from 10.8 ± 7.11% 
(A*03_BILF2VTLA) to 20.7 ± 23.7% (A*03_BALF3QVAT), 
comparable to the enrichment efficiency of A*03_
EBNA3ARLRA (19.4 ± 21.0%, Figure 6B). Concerning 
the enrichment of IFN-γ+CD8+ T cells, increases ranged 
on average from 95.0- (A*03_BILF2VTLA) to 184.9-
fold (A*03_BALF3QVAT). The enrichment of A*03_
EBNA3ARLRA-specific IFN-γ
+CD8+ T cells resulted in 
increases of 244.0-fold (Figure 6A and 6B).
The IFN-γ+CD8+ T cells were furthermore 
characterized by immunophenotyping. High proportions 
of TEM (37.9 ± 4.95%) and TEMRA (39.5 ± 6.99%) were 
assessed for each peptide before enrichment (Figure 6C). 
In comparison to TEMRA, slightly higher TEM proportions 
were found in response to A*03_BILF2VTLA, A*03_
BcRF1FLLA and A*03_BILF2LIIP with differences of 
7.12%, 3.20% and 18.1% (Figure 6C). The stimulation 
with A*03_BALF3QVAT however led to a 36.4% higher 
TEMRA proportion in relation to TEM. Similar frequencies 
of TEM (40.8%) and TEMRA (39.5%) were detected 
following stimulation with the reference peptide A*03_
EBNA3ARLRA. Regarding TCM proportions, frequencies 
ranged from 0% (A*03_BALF3QVAT) to 3.52% (A*03_
BILF2LIIP). The comparative analysis of the CD45RA
+ and 
of the CD45RA- frequencies showed on average a higher 
proportion of CD45RA+ T cells (60.4%) and a 20.9% 
lower frequency of CD45RA- T cells (39.6%, Figure 6C).
Improving the enrichment efficacy of EBV-specific T 
cells using peptide mixtures 
To confirm the suitability of the newly identified 
peptides for the generation of clinical-grade T cells, the 
additional antigen-specific stimulation with the three 
different mixtures was evaluated in comparison to the 
EBV_Consensus alone (Figure 6D–6E). The stimulation 
with EBV_Consensus+3PMIX resulted in the activation of 
IFN-γ+CD3+ T cells with a mean frequency of 0.25 ± 0.27% 
(Figure 6D), which was 17.2% higher in comparison to the 
mere EBV_Consensus (EBV_Consensus: 0.22 ± 0.26%, 
Figure 6D). The highest capacity was homogenously 
detected in all donors subsequent to a stimulation with 
EBV_Consensus+11PMIX. The stimulation with this mixture 
led to 174.4% more IFN-γ+CD3+ T cells (0.59 ± 0.51%, 
Figure 6D) and 205.9% more IFN-γ+CD8+ T cells 
(1.08 ± 0.94%, Figure 6D), as compared to the mere EBV_
Consensus. 
The proportions of IFN-γ+CD3+ T cells following 
enrichment revealed a donor-specific enrichment 
efficiency (Figure 6E). With respect to the different 
antigenic stimulations, the enrichment process in donor 
3 demonstrated a homogenous step-by-step enhancement 
of IFN-γ+CD3+ T cells. In donor 1 and 2, however, this 
process did not induce any higher proportions of IFN-
γ+CD3+ T cells than the EBV_Consensus alone (Figure 
6E). Taking the immunophenotypes of the IFN-γ+CD8+ 
T cells into account before and after the enrichment 
process, it becomes evident that the stimulation with one 
of these three mixtures triggered higher TEM (45.4 ± 3.44% 
TEM (Origin), 63.4 ± 4.75% TEM (Elution)) than TEMRA 
proportions (33.8 ± 1.13% TEMRA (Origin), 28.8 ± 4.89% 
TEMRA (Elution)). The mean frequency of TCM ranged from 
5.21 ± 4.87% to 10.2 ± 9.41% prior to the enrichment 
(data not shown). In summary, these findings highlight 
the suitability of the newly identified epitopes as antigenic 
stimulants for the generation of clinically applicable EBV-
specific T cells.
Clinical relevance of the newly identified highly 
immunodominant CTL epitopes in patients with 
EBV-associated PTLD
The relevance and clinical applicability of the 
highly immunodominant peptides A*03_BILF2VTLA, 
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Figure 4: (A–B) Confirmation of the EBV-derived peptides’ in vitro binding and dissociation. Peptide-binding efficiency on 
HLA-A*03:01 monomers and stability of the pHLA-A*03:01-complexes of the newly identified EBV-derived candidate-peptides (Table 1) 
were determined by (A) Flex-TTM MHC Tetramer assays (Flex-T assay) and by (B) T2 peptide binding and dissociation assays. Flex-T 
assays were carried out for all eleven candidate-peptides. A stable HLA class I monomer with a high-affinity, non UV-labile peptide 
as well as pMHC monomers for the known HLA-A*03:01-restricted CMV-IE1-specific peptide KLGGALQAK (A*03_IE1KLGG) and 
A*03_EBNA3ARLRA (Table 1) functioned as positive controls. Unloaded HLA-A*03:01 monomers (unloaded HLA-A*03:01) as well as 
pMHC monomers for the CMVpp65-derived peptides restricted to HLA-A*02:02 (NLVPMVATV, A*02_pp65NLVP) and HLA-B*07:02 
(TPRVTGGGAM, B*07_pp65TPRV), respectively, served as negative controls. (A) Efficiency of the pivotal exchange process was verified 
by a rapid streptavidin-capture ELISA and results are given as the optical density (OD), quantified at 414 nm absorbance. The stability 
of the pHLA-A*03:01-complexes in response to the four highly immunodominant EBV-derived peptides was investigated by T2 peptide 
binding and dissociation assays. Peptide-unloaded T2 cells served as negative control and the known immunodominant HLA-A*03:01-
restricted EBV-derived peptide RLRAEAQVK (A*03_EBNA3ARLRA) as reference. (B) The HLA class I expression levels as well as the 
peptide-MHC-complex dissociation were investigated at the given points of time (t1 = 0 min, t2 = 60 min, t3 = 120 min). The resultant 
fluorescence index (FI) was calculated as the mean fluorescence intensity (MFI) of HLA-A*03:01 on peptide-stimulated transduced T2 
cells and peptide-unloaded cells, respectively. In terms of a comparable reference the unloaded cells were standardized to 0. The results are 
shown as the mean of n = 3 independent experiments ± SD and statistically significant differences between the EBV-specific peptides and 
A*03_EBNA3ARLRA are asterisked (
*p < 0.05). 
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A*03_BcRF1FLLA and A*03_BALF3QVAT for PTLD and 
EBV-associated diseases were verified in HLA-A*03:01+ 
patients with EBV-associated PTLD after SOT. Peptide-
specific T-cell frequencies differed during the patients’ 
treatment (Figure 7A–7D, Supplementary Figure 4). A*03_
EBNA3ARLRA-specific CTLs were not detectable (Figure 
7A) in all patients, whereas for A*03_BILF2VTLA (Figure 
7B) and A*03_BcRF1FLLA (Figure 7C) well-defined peptide-
specific CD8+multimer+ populations were detected in each 
of the assessed patients. For the A*03_BALF2QVAT epitope 
(Figure 7D) well-defined CD8+multimer+ populations were 
found in only 40% of the patients. The multimer staining 
resulted in the detection of on average 1.33% A*03_
BILF2VTLA-specific CTLs (range: 0.09–5.52%, Figure 7B) 
and 0.52% A*03_BcRF1FLLA-specific CTLs (range: 
0–2.31%, Figure 7C). Both revealed on average higher 
frequencies in the patients’ blood than the applied reference 
A*03_EBNA3ARLRA (0.03% within CD8
+ T cells, range: 
0–0.65%, Figure 7A). These higher frequencies of A*03_
BILF2VTLA- and A*03_BcRF1FLLA-specific CTLs were in 
line with those of the peptide-specific CTLs detected in the 
assessed healthy donors (Figure 5), while the lowest mean 
frequency was discerned for A*03_BALF3QVAT (0.004%, 
range: 0–0.71%, Figure 7D). 
Interestingly, the highest frequencies for A*03_
BILF2VTLA (5.52%, Figure 7B), A*03_BcRF1FLLA (2.31%, 
Figure 5: Identification of peptide-specific CTL precursor frequencies in healthy donors by pMHC multimer staining. 
Precursor frequencies of EBV-specific CTLs directed against the peptides A*03_BILF2VTLA, A*03_BcRF1FLLA and A*03_BALF3QVAT were 
visualized via pMHC multimer staining, analyzed by flow cytometry and compared to the frequencies of the referential antigen A*03_
EBNA3ARLRA of freshly isolated PBMCs (day 0, n = 5). Findings are displayed as the mean percentage of CD8
+multimer+ T cells ± SD after 
subtracting the respective percent value of the general nonsense dextramer, which functioned as a negative control. 
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Figure 6: (A–E) Evaluation of the eligibility of the highly immunodominant HLA-A*03-restricted EBV-derived peptides for clinical 
application–by means of CSA. PBMCs from healthy donors (n = 3) were stimulated with one of the four highly immunodominant EBV-
peptides. Respective frequencies of the IFN-γ-secreting cell fractions before (origin) and after the enrichment (eluate) were determined by 
multicolor flow cytometry. Frequencies in the ‘origin’ evaluated in comparison to (A) the respective frequencies of the IFN-γ-secreting T 
cells in response to the EBV-derived reference peptide A*03_EBNA3ARLRA. (B) The efficiency of the IFN-γ-specific enrichment via the 
magnetic labeling of IFN-γ-secreting cells is separately shown for each of the assessed peptides. (C) Phenotypic analyses regarding naïve 
(TN), central memory (TCM), effector memory (TEM) and terminally differentiated effector memory (TEMRA) T cells were performed for the 
IFN-γ+CD8+-secreting T cells of both aliquots (I: Origin, II: Eluate) and are visualized by the respective mean frequencies. To determine 
the peptides’ aptitude to enhance the stimulating efficacy of the EBV_Consensus, three mixtures of the in vivo isolated peptides and the 
EBV_Consensus were used as stimulating antigens (EBV_Consensus+3PMIX, EBV_Consensus+4PMIX, EBV_Consensus+11PMIX, Table 1). 
The frequencies of the different cell fractions in the ‘origin’ (n = 6) are individually displayed (donor 1 = , donor 2 = , donor 3 = ▲, 
donor 4 = ○, donor 5 = � donor 6 = Δ) in comparison to the respective percent values of the (D) IFN-γ+CD3+-secreting T cells, IFN-γ+CD8+-
secreting T cells and IFN-γ+CD4+-secreting T cells, respectively, induced by the mere EBV_Consensus. The efficiency of the enrichment 
is furthermore individually shown for each of the donors (n = 6) using the percent values of (E) the IFN-γ+CD3+-secreting T cells, the IFN-
γ+CD8+-secreting T cells and the IFN-γ+CD4+-secreting T cells. Findings are displayed as individual results and as the mean percentage of 
IFN-γ+ T cells ± SD.
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Figure 7C) and A*03_BALF3QVAT (0.71%, Figure 7D) 
were detected in the blood of patient 4 prior to the second 
rituximab therapy. Before administering the fourth 
rituximab dose to patient 4, solely frequencies of A*03_
BILF2VTLA-specific CTLs continued to be discernible 
(0.30%, Figure 7B) in contrast to A*03_BcRFFLLA (Figure 
7C) and A*03_BALF3QVAT (Figure 7D). 
Concisely, EBV-specific T cells of differing 
frequencies were detectable in response to all investigated 
peptides in patients with PTLD. These differing 
frequencies underline the importance of knowing a broad 
spectrum of pathogen-specific T-cell epitopes, which 
would enable the monitoring of specific T-cell frequencies.
SUMMARY
In this study, eleven novel EBV-specific CTL 
epitopes deriving from nine different EBV-proteins 
were isolated in vivo and selected by epitope prediction 
tools. All eleven CTL epitopes were identified as 
immunodominant by strong cytokine secretion and 
cytotoxicity. The four peptides A*03_BILF2VTLA, A*03_
BcRF1FLLA, A*03_BALF3QVAT and A*03_BILF2LIIP 
were classified as highly immunodominant. The clinical 
relevance was verified by detection of the respective 
antiviral CD8+ T-cell frequencies specific to three of these 
epitopes in patients with EBV-associated PTLD. The 
eligibility for adoptive immunotherapy was confirmed 
regarding the four highly immunodominant CTL epitopes 
by CSA, when being applied as single stimulants and in 
combination with an already established peptide pool. 
DISCUSSION
To improve the clinical outcome of patients suffering 
from EBV-associated post-transplant complications the 
present study aimed at the identification of novel, naturally 
presented and thus in vivo relevant EBV-derived T-cell 
epitopes suitable to (1) monitor EBV-specific immunity 
and to (2) generate highly efficient and clinically relevant 
T-cell products. The given experimental approach is 
a proof of concept with well-suited eligibility for the 
identification of novel epitopes restricted to specific HLA 
alleles, potentially applicable to further HLA alleles and/
or target antigens. 
Adoptive immunotherapy with EBV-specific T 
cells: Advantageous potential of peptides and 
their limitations 
Adoptive immunotherapy with EBV-specific T 
cells provides a personalized, targeted and non-toxic 
immunotherapeutic strategy for the immediate and 
long-term protection of the patients’ EBV-specific 
immunity. This promising therapeutic approach is 
however limited by the high antigenic diversity due to 
distinct, latency-associated gene and protein expression 
profiles, the HLA-restrictions as well as limited by the 
low immunodominance of known EBV epitopes [24]. 
Icheva et al. demonstrated that the adoptive transfer of 
EBNA1-specific T cells to patients with EBV viremia and/
or PTLD after HSCT is safe as neither GvHD (>grade 2) 
nor acute toxicity have been detected [13]. Since EBNA1 
is the EBV protein to be expressed in all three latency 
states and relevant to EBV-associated PTLD, it represents 
one of the most promising antigenic targets [55]. In 80% 
of the patients, in vivo expansion of EBNA1-specific T 
cells could be observed and in 70% of them clinical and 
virological responses were detected, whereas 30% of the 
PTLD patients did not reveal any kind of effective immune 
response [13]. These findings highlight the fact that known 
EBNA1-derived epitopes are of low immunogenicity, 
thus leading to low frequencies and weak cytotoxic T-cell 
responses [47, 55, 56]. So far, this impedes the therapeutic 
efficacy of adoptive immunotherapy for EBV-associated 
diseases in immunocompromised patients.
The major challenge of developing and improving 
immunotherapeutic strategies is therefore to overcome 
these limitations. Mixtures of multiple immunogenic 
peptides instead of single peptides deriving from one or 
more EBV-specific proteins and covering multiple HLA 
class I and II alleles were found to be advantageous [1, 
57] by inducing EBV-specific T cells of higher antigenic 
diversity, essential to an effective treatment of EBV-
associated PTLD [17, 58]. Recently, Nowakowska et al. 
have detected an enhanced stimulating efficacy by the use 
of a mixture of peptides deriving from 16 latent and lytic 
EBV proteins in comparison to the stimulation with peptide 
pools covering just sequences of either EBNA1, LMP2A, 
BZLF1 or EBNA3C [58]. Consequently, a larger pool of 
antigens derived from various EBV proteins with different 
HLA restriction elements reveals to be more efficacious and 
leads to higher response rates resulting in the activation of 
a greater EBV-specific memory T-cells’ repertoire [17, 58]. 
Moosmann et al. rapidly generated and isolated 
EBV-specific T cells by using a pool of 23 EBV peptides 
deriving from 11 EBV proteins [17]. This peptide pool 
covered the most frequent, but not all HLA-class I and 
II alleles [17]. The commercially available peptide pool 
PepTivator EBV Consensus (Miltenyi Biotec, indicated 
as ‘Select’ in GMP grade), containing 43 peptides and 
deriving from 13 different lytic and latent EBV-proteins, 
is likewise restricted to 14 frequent HLA-class I and II 
molecules. Since the stimulation spectrum is exclusively 
narrowed to those alleles represented in these pools, 
even the latter are not irrespective of the donor’s HLA-
type. This emphasizes the necessary enlargement of the 
repertoire of T-cell epitopes restricted to certain, currently 
underrepresented HLA-alleles [47]. For validation of the 
hereby applied experimental approach to broaden the 
HLA-coverage of these overlapping EBV-specific peptide 
pools, the given study focused on the HLA-A*03:01-
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allele, as only few EBV-specific HLA-A*03:01-restricted 
epitopes have been identified, only two epitopes restricted 
to HLA-A*03:01 have been commercially available 
(EBNA3A: RLRAEAQVK, BRLF1: RVRAYTYSK, [47]) 
and have therefore been primarily used as HLA-A*03:01-
restricted stimuli (e.g. [17, 58]).
Highly immunotherapeutic potential of the 
newly identified EBV-derived peptides 
EBV-specific peptides were isolated in vivo from 
deliberately chosen EBV-infected sHLA-A*03:01-
transduced B-LCLs, expressing all ten EBV-latency-
Figure 7: (A–D) Verification of clinical relevance of the newly identified highly immunodominant CTL epitopes for EBV-associated 
PTLD. The clinical relevance of the highly immunodominant EBV-derived peptides (A*03_BILF2VTLA, A*03_BcRF1FLLA, A*03_
BALF3QVAT) and the known immunodominant EBV-derived peptide (A*03_EBNA3ARLRA) for EBV-associated PTLD was verified by 
pMHC multimer staining and analyzed by multicolor flow cytometry. The respective frequencies of peptide-specific CD8+multimer+ T cells 
in HLA-A*03:01-positive patients suffering from EBV-associated PTLD were visualized by separately displaying the detected frequencies 
at two different points of time in the course of their treatment (n = 5). In order to exclude false-positive cells due to unspecific background 
level the general nonsense was applied and its respective percent value was subtracted from the patients’ frequencies specific to one of 
the peptides. At the time of blood withdrawal patients were prior to receiving their second, third, fourth or fifth treatment with rituximab, 
after their sixth treatment with rituximab, in follow-up care ensuing cytotoxic chemotherapy (a) or in follow-up care subsequent to no other 
treatment than rituximab (b). The resultant precursor frequencies of peptide-specific CD8+multimer+ T cells are shown as follows: (A) 
A*03_EBNA3ARLRA, (B) A*03_BILF2VTLA, (C) A*03_BcRF1FLLA and (D) A*03_BALF3QVAT. 
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associated proteins of latency state III and therefore 
representing a surrogate for PTLD [5, 55]. This was done 
to guarantee the clinical relevance for EBV-infections, 
-reactivations and EBV-associated PTLD and to ensure 
the in vivo natural presentation of the candidate-epitopes. 
Eleven in vivo isolated EBV-specific HLA-A*03:01-
restricted T-cell epitopes were identified as potential 
targets by use of different epitope prediction tools 
and further on evaluated in terms of immunogenicity. 
All of them revealed to be immunodominant (≥20% 
response rate) and four of them were classified as highly 
immunodominant (Table 1). Subsequent to a short-term 
in vitro stimulation, the frequencies of T cells specific to 
the newly identified CTL epitopes in healthy donors were 
lower in comparison to the known latent EBNA3A-derived 
A*03_EBNA3ARLRA. However, the long-term in vitro 
stimulation period of seven days homogenously confirmed 
the epitopes’ potential to expand EBV-specific T cells 
shown by an increase in the respective T-cell frequencies. 
Despite the higher frequencies ensuing short-term in 
vitro stimulation, A*03_EBNA3ARLRA is less appropriate 
for a long-term in vitro stimulation of peptide-specific 
CTLs than the newly identified epitopes, in particular the 
four highly immunodominant ones. The identification of 
best-suited T-cell donors (e.g. HSCT, family or unrelated 
third-party T-cell donors) is predominantly based on the 
respective starting frequencies, but the T-cells’ potential to 
expand and to provide the most effective subsets as well 
as phenotypes is also essential to improve the therapeutic 
effect of the adoptively transferred CTLs [17, 57]. 
In this context, cytotoxic CD8+ T cells specific 
to the highly immunodominant epitopes revealed high 
proportions of both TEM and TEMRA. TEM were shown 
to have the highest effector function in terms of viral 
clearance [59, 60]. Moosmann et al. demonstrated that 
CD8+ T cells after being transferred either unveiled a 
CCR7+CD45RA- central memory or a CCR7-CD45RA+ 
terminal effector phenotype and both subsets were 
consistent with long-term T-cell persistence and capable of 
controlling viral reactivations after PTLD remission [17]. 
Correspondingly, the immunophenotype of the cytotoxic 
CD8+ T cells specific to the four highly immunodominant 
epitopes unveiled to be essential to an effective adoptive 
immunotherapy.
Proof of clinical relevance by monitoring EBV-
specific T cells in patients suffering from EBV-
associated disease
The clinically relevant natural processing and 
presentation of three of the highly immunodominant 
epitopes (A*03_BILF2VTLA, A*03_BcRF1FLLA, A*03_
BALF3QVAT) was confirmed by peptide-specific T-cell 
frequencies detected in HLA-A*03:01+ patients with 
EBV-associated PTLD. Although a detailed follow up in 
patients was not feasible due to material shortage, it was 
interesting that the highly variable peptide-specific CTL 
frequencies were similar to those in healthy donors and 
will therefore need to be more thoroughly investigated 
in larger patient and donor cohorts. In this context, the 
cytolytic activity of these peptide-specific CTLs against 
tumor cells of HLA-A*03:01+ patients with EBV-
associated PTLD should additionally be reaffirmed in 
future studies. 
Clinical relevance of the identification of a broad 
pathogen-specific epitope repertoire for adoptive 
immunotherapy
In addition to the peptides’ capacity to elicit 
functional T-cell-mediated immune responses against EBV, 
their aptitude to reinforce commercially available peptide 
pools was equally investigated. In line with the findings of 
Nowakowska et al. [58], the results of this study clearly 
demonstrated the reinforcement of the pool’s stimulating 
efficacy when a certain mixture of the novel epitopes 
is added to the peptide pool EBV_Consensus. Since a 
higher number of epitopes in such a mixture, particularly 
of those restricted to one HLA-allele, might raise 
concerns about antigenic competition, we examined three 
different mixtures [61]. The CSA, a small-scale technique 
related to the large-scale CliniMACS system for the 
manufacturing of clinical-grade antigen-specific T cells, 
showed a step-by-step enhancement of the EBV-specific 
IFN-γ+CD3+ T-cell stimulating efficacy in response to 
EBV_Consensus+3PMIX (17.2%), EBV_Consensus+4PMIX 
(28.8%) and EBV_Consensus+11PMIX (174.4%) as 
compared to the mere EBV_Consensus (Figure 6D). 
Based on this gradual enhancement, antigenic competition 
within the mixture is not suspected. Nonetheless, as the 
addition of three highly immunodominant peptides (EBV_
Consensus+3PMIX) already achieved on average a 22.7 
higher percentage value regarding the IFN-γ+CD8+ T cells 
in comparison to the mere EBV_Consensus prior to the 
enrichment (Figure 6D), this mixture represents the safest 
option to obviate any possible antigenic competition. 
IFN-γ+CD8+ T cells specific to EBV_Consensus+3PMIX 
showed a T-cell phenotype with high proportions of TEM 
and TEMRA (78.5%) before the enrichment, hence essential 
for an effective EBV-clearance. Thus, the addition of a 
combination of the newly identified epitopes to EBV_
Consensus revealed to enhance the stimulating efficacy of 
the mere pool without causing antigenic competition. 
Apart from predominantly inducing an EBV-specific 
IFN-γ+CD8+ T-cell response, relevant to an immediate 
immune reconstitution and a functional EBV clearance 
[62–64], frequencies of IFN-γ+CD4+ T cells were also 
detected following the stimulation with the assessed 
mixtures, thus suggesting that the nona- or decamers 
might also function as efficient CD4+ T-cell epitopes 
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when 2 to 4 amino acids were added to the respective 
sequences. As the CD4+ T-cell immunity is essential for 
long-term immunity, direct antiviral effector functions 
and for sustaining the CD8+ mediated immune response, 
particularly memory functions [11, 58, 65], these findings 
could additionally result in a further enhancement of the 
efficacy of the newly identified EBV-derived peptides and 
of the three mixtures [11, 65]. 
Since higher CD4+ T-cell frequencies in the infused 
EBV-specific T-cell products have furthermore been related 
to a better response [24], the best-suited ratio of CD8+ to 
CD4+ T-cells is to be identified in future studies, so that 
a certain, best functional ratio of both T-cell subsets can 
deliberately be induced to reinforce the adoptive transfer. 
Stable binding of the newly identified epitopes to 
pMHC complexes 
In addition to proving immunogenicity, cytotoxic 
activity and clinical relevance of the newly identified 
EBV-specific T-cell epitopes, their binding efficiency and 
the stability of their pMHC complexes were furthermore 
assessed. The resultant findings of the in vitro Flex-T and 
T2 binding/dissociation assays correlated and mostly led to 
similar findings as the respective in silico predicted scores 
of the constantly improved epitope prediction tools [39, 42, 
66]. Their algorithms enable a first selection and ranking 
based on predictions regarding the most pivotal aspects 
of a natural peptide presentation [39, 41, 42, 66, 67], 
but neither do they guarantee the definite accuracy of the 
epitope’s behavior and its immunogenicity in the in vivo 
setting nor do they reflect one-to-one correlations with 
either in vivo or experimental data. 
The peptide A*03_BILF2VTLA for instance 
demonstrated a similar ability to stabilize pMHC complexes 
on the cell surface of T2 cells at time point t3 likewise to 
the one of the reference peptide A*03_EBNA3ARLRA, 
although the predicted half-time dissociations of both 
peptides varied strongly (NetMHCstab, www.cbs.dtu.dk/
services/NetMHCstab-1.0). A significant consequence of 
this aforementioned incongruity is the fact that peptide 
sequences might not be stable enough to survive the 
individual steps of the multimer synthesis. Thus, the 
synthesis of peptide-specific pMHC multimers useful 
for the distinct detection might fail, although respective 
peptide-sequences have been isolated from in vivo and 
elicited an EBV-specific immune response as detected by 
in vitro T-cell immunoassays. 
For instance, specific T cells against the peptide 
A*03_BILF2LIIP have been detected in 55% of the healthy 
donors of this study, nevertheless its multimer synthesis 
failed, possibly due to the sequence’s particular composition 
of amino acids since it consists of the highest number of 
seven hydrophobic amino acids that easily dissociate and 
not of one of the preferred residues at P9. Although it has 
been suggested that two preferred anchors represent a 
condition for a stable MHC class I interaction [68], A*03_
BILF2LIIP has not unveiled the fastest dissociation in the in 
vitro dissociation assay and manifested the highest peptide-
binding affinity at time point t1 (Figure 4B). 
In this context the Flex-T technology reveals to 
be suitable, as pMHC monomers can be generated for 
a peptide of interest, subsequently be multimerized and 
used for staining peptide-specific CD8+ T cells. This 
method allows both the assessment of pMHC complex 
stability for individual peptides and a fast generation of 
the corresponding pMHC multimer. As the generation 
of these multimers is immediately carried out before the 
T-cell staining, this technology might enable generating 
multimers for pMHC complexes, which are characterized 
by a fast dissociating stability and might therefore allow 
the analysis of their respective T-cell populations. These 
findings highlight the unavoidable disparity between 
the immunogenicity in the in vivo setting, the synthetic 
production and the in silico approach as for the peptide 
binding and stability. 
Future prospects: Establishment of the 
most suitable EBV-specific peptide pool for 
immunomonitoring and adoptive T-cell therapy
The experimental approach being described has 
proven to be a well-suited procedure to identify further 
HLA-restricted epitopes, consequently appropriate 
to enhance the stimulating efficacy of an established 
peptide pool as well as to broaden its HLA-coverage. 
This might overcome current limitations of the adoptive 
immunotherapy’s success regarding EBV-infections, 
-reactivations or EBV-associated PTLD and possibly 
reduce the risk of tumor escape mutants as the latter might 
subsequently occur to the antigenic stimulants with pools 
covering sequences from merely one EBV protein [58]. 
Hence, future studies should aim at the establishment 
of the most suitable pool of both EBV-specific peptides 
derived from clinically relevant EBV proteins and of high 
HLA diversity, enabling the accurate immunomonitoring 
in patients, especially in those at high risk, as well as the 
selection of highly pure and functional EBV-specific T 
cells in sufficient numbers for adoptive transfer.
MATERIALS AND METHODS
Study population
All experiments were performed with residual 
blood samples from platelet (PLT) apheresis disposables 
used for routine PLT collection of regular anonymous 
healthy donors of the Hannover Medical School (MHH) 
Institute for Transfusion Medicine. Informed consent 
was obtained from all donors as approved by the Ethics 
Committee of Hannover Medical School, and trial subject 
data were treated as confidential information protected by 
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medical confidentiality. The donors’ HLA-class I and II 
alleles were identified at four-digit resolution by means 
of sequence-based subtyping [28] and their EBV-serology 
was determined by performing confirmatory Western 
blot assays designated to detect anti-EBV IgG antibodies 
(recomLine EBV IgG, Mikrogen). Peripheral blood from 
either HLA-A*03:01–EBV+ or HLA-A*03:01+EBV– 
healthy donors served as controls. 
Lentiviral transduction of soluble HLA-A*03:01 
molecules into EBV-transformed B-LCLs
Three HLA-A*03:01+ EBV-transformed B-LCLs 
(EBV+B-LCLs: B-LCL024, B-LCL623, B-LCL1335) were 
cultivated in RPMI1640 (Lonza) supplemented with 10% 
heat-inactivated fetal calf serum (FCS, Biochrom) [29]. 
The EBV+B-LCLs were transduced with lentiviral vectors 
expressing sHLA-A*03:01 (sA*0301.pRRL.SFFV.mcs), 
as previously described [30, 31]. Secretion levels of 
sHLA-A*03:01 were regularly determined via quantitative 
w6/32-antibody ELISA [32], and compared to the 
background level of each of the respective untransduced 
EBV+B-LCLs.
Purification and subsequent isolation of in vivo 
HLA-A*03:01-restricted EBV-derived peptides
Highly sHLA-A*03:01-productive clones were 
cultivated in two-compartment bioreactors (CELLine 
Classic 1000, INTEGRA-Biosciences). Supernatants 
were regularly harvested, pooled, and used for isolation 
of peptides of the sHLA-A*03:01 complexes by 
immunoaffinity chromatography with anti-HLA-ABC 
monoclonal antibody (mAb) w6/32 (Serotec) [33–35]. 
Pool sequencing was performed by nano-LC-ESI-MS/
MS analysis and mass spectrometry was done in order to 
identify the peptide-sequences (TopLab) [36].
Identification of EBV-derived candidate-epitopes 
by different epitope prediction tools
Mascot database queries (www.matrixscience.
com, [37]) were carried out using an EBV-specific 
database from UniProtKB (www.uniprot.org) 
(Supplementary Figure 1). The resultant EBV-derived 
peptide-sequences were preliminarily sorted, excluding 
sequences with lower peptide-ion-scores than ten 
[38]. The remaining, coarsely filtered sequences were 
ranked downwards and were then screened in respect 
to their HLA-A*03:01-restricted binding affinity and 
complex stability by using the epitope prediction tools 
NetMHC 4.0 (www.cbs.dtu.dk/services/NetMHC, [39, 
40]), NetCTL 1.2 (www.cbs.dtu.dk/services/Netctl, 
[41]) and NetMHCstab 1.0 (www.cbs.dtu.dk/services/
NetMHCstab-1.0, [42]). Peptide-sequences were ranked 
in accordance to their predicted %RANK (NetMHC) 
and a cut-off value for sequences with affinities rating 
below 15%RANK was applied. The prediction results 
for the 20 highest scoring sequences of each of the three 
B-LCLs and those identified as strong [SB] or weak 
binders [WB] (NetMHC) were subsequently verified 
by SYFPEITHI (www.syfpeithi.de, [43]) and ExPASy-
ProtParam-tool (www.expasy.org/protparam, [44]). To 
obviate alloreactivity, the sequences still remaining 
potentially relevant were screened with regard to 
homologies within the human genome using BLAST-
UniProtKB (www.uniprot.org/blast). Additionally, the 
relevant sequences were reviewed with focus on those 
derived from proteins associated with EBV+-PTLD, 
-latency, -reactivation and/or with potentially malignant 
transformation. Ultimately, the respective sequences 
were verified whether to reflect the HLA-A*03:01-
specific peptide supermotif [45, 46]. 
Peptides of the eleven highest scoring EBV-specific 
candidate-epitopes (Table 1) were synthesized (95% 
purity, EZBiolab) and used for in vitro studies to assess 
their immunogenic potential. 
Short- and long-term stimulation assays to 
screen for effector molecule secretion in response 
to EBV-derived candidate-peptide 
The immunogenic potential of EBV-derived peptides 
was evaluated by functional immunoassays. PBMCs were 
isolated from blood of healthy HLA-A*03:01+EBV+ 
donors by density gradient centrifugation. Freshly isolated 
PBMCs were rested overnight (at 37°C, 5% CO2) at a 
density of 1 × 107 cells/well (24-well-plate, Sarstedt) 
prior to short- (overnight) and long-term (7 days) in vitro 
stimulation. The known HLA-A*03:01-restricted EBV-
derived peptide RLRAEAQVK (A*03_EBNA3ARLRA, 
ProImmune [17, 47]) and the peptide pool PepTivator 
EBV Consensus (EBV_Consensus, Miltenyi Biotec) have 
consistently been used as referential stimulating antigens. 
On day 1, cells at a density of 5 × 106 cells/well 
(24-well-plate, at 37°C, 5% CO2) were stimulated with 
one of the eleven EBV-specific peptides (10 μg/ml) or 
with EBV_Consensus+4PMIX (Table 1) consisting of a 
combination of EBV_Consensus (1μg per peptide/ml) 
and the four highly immunodominant peptides (10 μg per 
peptide/ml). Cells were expanded in TexMACS-medium 
(Miltenyi Biotec) supplemented with 0.5 μl/ml interleukin 
(IL)-2 and 1 μl/ml IL-7 (both PeproTech) over 7 days. 
Detection of the effector molecules IFN-γ and 
granzyme B by EliSpot, ELISA and FluoroSpot
IFN-γ EliSpot assays allow to simultaneously 
detect antigen-specific T cells at a single cell level based 
on their IFN-γ secretion in a high number of donors and 
to use a variety of different stimuli. The assays were 
performed after short- and long-term in vitro stimulation, 
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as previously described [25, 27], using precoated EliSpot 
plates (Lophius biosciences). Negative and positive 
controls were carried out by using either solitary medium 
or 1 μg/ml staphylococcal enterotoxins B (SEB, Sigma 
Aldrich). Resultant findings are indicated as number of 
spw, representing the number of spots in the antigen well 
after subtracting those of the respective negative control 
well. A resultant value >3 spw was defined as a positive 
response. Results were furthermore obtained as spw/1000 
CD3+ T cells.
The functionality of the induced T cells was 
also determined by detection of the secretion levels 
of the effector molecules IFN-γ and granzyme B in the 
supernatants after long-term in vitro stimulation using 
quantitative ELISA (both eBioscience). FluoroSpot 
assays were furthermore performed, as they are apt to 
simultaneously detect the secretion of IFN-γ and granzyme 
B (Mabtech). PBMCs were plated at a density of either 
2.5 × 105 (peptide pool stimulation) or 5.0 × 105 cells/
well (single peptide stimulation) on precoated FluoroSpot 
plates (in RPMI1640/10% AB serum) and subsequent to 
their peptide-specific stimulation, they were incubated 
for a period of 45 hours. To enhance the stimulation the 
anti-CD28 mAb was included. Negative and positive 
controls were carried out by using either solitary medium 
or anti-CD3 mAb. Apart from EBV_Consensus+4PMIX, 
(Table 1) EBV_Consensus (2.5 × 105 cells/well) was 
either mixed with a mixture of the three EBV-derived 
peptides (EBV_Consensus+3PMIX, Table 1), revealing 
the highest response rates (>60%) in first preliminary 
screenings, or with all eleven newly identified peptides 
(EBV_Consensus+11PMIX, Table 1). Spots identified with 
the filter for fluorescein isothiocyanate (FITC) represented 
IFN-γ producing cells and spots identified by the filter for 
Cyanine 3 (Cy3) detected granzyme B producing cells. 
Results are indicated as number of spw, equal to the 
number of spots in the antigen well after subtracting those 
of the respective negative control well. 
HLA class I peptide binding and dissociation 
assays 
Flex-TTM MHC Tetramer assays (Flex-T assay) 
and T2 peptide binding and dissociation assays were 
performed to confirm peptide binding and stability of the 
pHLA-A*03:01-complexes. 
Flex-TTM MHC Tetramer assays (BioLegend) were 
carried out according to manufacturers’ instructions. 
Briefly, each of the eleven candidate-peptides was loaded 
into the binding site of the HLA-A*03:01 groove by using 
UV light source to degrade the UV-labile peptide. The 
exchange process was verified by a rapid streptavidin-
capture ELISA. As positive controls functioned a stable 
HLA class I monomer with a high-affinity, non UV-labile 
peptide as well as pMHC monomers for the reference 
A*03_EBNA3ARLRA and the known HLA-A*03:01-
restricted CMV_IE1-specific peptide KLGGALQAK 
(A*03_IE1KLGG, ProImmune). Unloaded HLA-A*03:01 
monomers as well as HLA-A*03:01 monomers loaded 
with HLA-A*02:01-(NLVPMVATV, A*02_pp65NLVP, 
ProImmune) and B*07:02-restricted (TPRVTGGGAM, 
B*07_pp65TPRV, ProImmune) peptides, respectively served 
as negative controls. 
T2 peptide binding and dissociation assays were 
carried out as previously described [48–51]. TAP deficient 
T2 cells had been transfected to express membrane-bound 
HLA-A*03:01 [52]. 2 × 106 T2 cells/ml were plated on 
a 96-well-plate in 100 μl serum-free RPMI1640 and 
stimulated with 50 μg/ml of the respective peptide and 
additional 5 μg/ml beta-2 microglobulin (ß2M, Sigma) 
for 14–18 hours (37°C, 5% CO2). Peptide-unloaded 
cells served as negative control and the known peptide 
A*03_EBNA3ARLRA as reference. The mAb FITC-labeled 
anti-HLA-ABC (w6/32, AbD Serotec) was employed 
to evaluate the HLA class I expression levels by flow 
cytometry (FACSCanto 10c, FACSDiva V8.0.1 software, 
BD Biosciences). For pMHC-complex dissociation assays, 
peptide-loaded cells were washed with Phosphate-buffered 
saline (PBS (Lonza) after incubation and resuspended in 
RPMI1640/2% FCS. Aliquots of cells were collected at the 
indicated time points (t1 = 0 min, t2 = 60 min, t3 = 120 min) 
and analyzed by flow cytometry using anti-w6/32-FITC 
mAb [48]. The resultant fluorescence index (FI) was 
calculated as the mean fluorescence intensity (MFI) of 
HLA-A*03:01 on peptide-loaded and -unloaded T2 cells, 
respectively in order to visualize the dissociation degree at 
different time points. In terms of a comparative reference 
the unloaded T2 cells were standardized to 0. 
Enrichment efficiency of EBV peptide-specific T 
cells by cytokine secretion assay
The non-GMP IFN-γ CSA (Miltenyi Biotec), is a 
small-scale procedure on the basis of the clinical-scale 
CliniMACS system. Results obtained by CSA show the 
tendency to mirror the enrichment efficacy of clinical -grade 
antigen-specific T cells. CSA was performed according 
to the manufacturer’s instructions and used (1) to verify 
the immunogenicity of the newly identified epitopes 
and (2) to predict the T-cell enrichment efficiency 
[53, 54]. Unstimulated cells served as negative control 
while A*03_EBNA3ARLRA and the PepTivator EBV 
Consensus, respectively were used as references. PBMCs 
were either stimulated with the highly immunodominant 
candidate-peptides (A*03_BILF2VTLA, A*03_BcRF1FLLA, 
A*03_BALF3QVAT and A*03_BILF2LIIP, Table 1) alone 
or with one of the three different mixtures of the in 
vivo isolated peptides and EBV_Consensus (EBV_
Consensus+3PMIX, EBV_Consensus+4PMIX, EBV_
Consensus+11PMIX, Table 1). Aliquots of the respective 
cell fractions before (origin) and after enrichment 
(elution) were analyzed by multicolor flow cytometry. To 
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distinguish between naïve (TN: CD62L
+CD45RA+), central 
memory (TCM: CD62L
+CD45RA−), effector memory (TEM: 
CD62L−CD45RA−) and terminally differentiated effector 
memory T cells (TEMRA: CD62L
−CD45RA+), cells were 
stained in addition to anti-IFN-γ-phycoerythrin mAb (PE, 
Miltenyi Biotec) with the following antibodies: FITC-
labeled anti-CD3 mAb, allophycocyanin (APC)-labeled 
anti-CD8 mAb, APC-Cy7-labeled anti-CD45 mAb (all 
BioLegend) and Alexa Fluor (AF) 700-labeled anti-CD4 
mAb, Brilliant Violet (BV) 421-labeled anti-CD62L mAb, 
BV 510-labeled anti-CD45RA mAb and BV 605-labeled 
anti-CD27 mAb (all BD Bioscience). Distribution of 
viable and dead cells was done by 7-aminoactinomycin 
(AAD)-staining. In the viable CD45+7AAD−-leukocyte-
gate at least 10,000 events were acquired. 
Visualization of EBV-specific T cells by pMHC 
mutimer staining 
The pMHC multimer staining technology allows 
the direct visualization of antigen-specific T cells in the 
blood of potential donors and patients. Staining was 
meant to confirm the clinical relevance of the highly 
immunodominant candidate-epitopes (Table 1) by detecting 
CD8+ CTL frequencies specific to the newly identified 
epitopes. Blood samples from HLA-A*03:01+ patients 
(n = 5) with EBV-associated PTLD were obtained at two 
different time points during their therapy: prior to receive 
the second, third, fourth or fifth treatment with Rituximab, 
after their sixth treatment with Rituximab, in follow-up 
care ensuing cytotoxic chemotherapy or in follow-up care 
subsequent to no other treatment than Rituximab. Specific 
CD8+ CTL frequencies were additionally visualized in 
freshly isolated PBMCs of healthy HLA-A*03:01+ donors 
(n = 5). To safeguard specific detection, pMHC multimer 
staining was also performed with cells from HLA-A*03:01- 
donors. Multimers (PE-conjugated dextramers, 
IMMUDEX) for three of the four highly immunodominant 
EBV-derived CTL epitopes were successfully synthesized. 
The synthesis of A*03_BILF2LIIP unfortunately failed. The 
general nonsense dextramer was applied to exclude false-
positive results, while the A*03_EBNA3ARLRA dextramer 
served as reference. Phenotypic T-cell characterization was 
carried out using the following mAbs: anti-CD3-FITC, 
anti-CD8-APC, anti-CD45-APC-Cy7 (all BioLegend), anti-
CD4-AF700, anti-CD62L-BV421, anti-CD45RA-BV510 
and anti-CD27-BV605 (all BD Bioscience). For viability 
staining 7-AAD was included. Gating was carried out in 
accordance with the light scatter properties of lymphocytes 
and CD3+ T-cell populations. With at least 100,000 events 
in the lymphocyte gate, the focus of the gating strategy was 
set on the CD3+CD8+ T cells in order to assess multimer+ T 
cells. Additionally, it was verified whether a well-defined 
cell population could be identified. Resultant frequencies 
are given as percent values after subtracting those of the 
respective general nonsense dextramer.
Statistical analysis
Statistical analysis was performed by Prism v5.02 
software (GraphPad). Generated data were analyzed using 
either non-parametric Mann-Whitney U-tests or one-way 
ANOVA and Bonferroni tests. Results were presented as 
means ± standard deviation (SD) and levels of significance 
expressed as p-values (*p < 0.05, **p < 0.01, ***p < 0.001). 
Significant differences have been detected in comparison 
to the referential antigens (A*03_EBNA3ARLRA, EBV_
Consensus).
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